<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02106845</url>
  </required_header>
  <id_info>
    <org_study_id>16674</org_study_id>
    <secondary_id>2013-003613-18</secondary_id>
    <nct_id>NCT02106845</nct_id>
  </id_info>
  <brief_title>Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.</brief_title>
  <official_title>A Phase I, Multi-center, Non-randomized, Open Label, Drug-drug-interaction Study to Determine the Effect of Multiple Doses of Regorafenib (BAY 73-4506) on the Pharmacokinetics of Probe Substrates of Transport Proteins P-gp (Digoxin; Group A) and BCRP (Rosuvastatin; Group B) in Patients With Advanced Solid Malignant Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the effect of regorafenib on the pharmacokinetics of digoxin (P-gp substrate :
      P-glycoprotein) and rosuvastatin (BCRP substrate: Breast cancer resistant protein) by
      comparing their Area under time curve (AUC(0-24)) and maximum drug concentration (Cmax) on
      Day -7 and Cycle 1 or Cycle 2 Day 15 of regorafenib in cancer patients
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 22, 2014</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">April 27, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24)) for Digoxin</measure>
    <time_frame>On Pre-Cycle Day -7 and on Cycle 1 Day15 or Cycle 2 Day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum drug concentration (Cmax) in plasma for Digoxin</measure>
    <time_frame>On Pre-Cycle Day -7 and on Cycle 1 Day15 or Cycle 2 Day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24)) for rosuvastatin</measure>
    <time_frame>On Pre-Cycle Day -7 and on Cycle 1 Day15 or Cycle 2 Day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum drug concentration (Cmax) in plasma for rosuvastatin</measure>
    <time_frame>On Pre-Cycle Day -7 and on Cycle 1 Day15 or Cycle 2 Day 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor Response following RECIST criteria</measure>
    <time_frame>From first dose up to 3 months after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Up to 30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with drug related adverse events as a measure of safety and tolerability</measure>
    <time_frame>Up to 30 days after last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>P-gp probe substrate(digoxin)+regorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: BCRP probe substrate (rosuvastatin) + regorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin</intervention_name>
    <description>Single dose of digoxin 0.5 mg (2 tablets 0.25 mg) orally without and with regorafenib</description>
    <arm_group_label>P-gp probe substrate(digoxin)+regorafenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Single dose of rosuvastatin 5mg (1 tablet 5 mg) without and with regorafenib 160 mg q.d. (4 tablets 40 mg)</description>
    <arm_group_label>Group B: BCRP probe substrate (rosuvastatin) + regorafenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib (Stivarga, BAY73-4506)</intervention_name>
    <description>Once daily orally 160 mg (4 tablets 40 mg)</description>
    <arm_group_label>P-gp probe substrate(digoxin)+regorafenib</arm_group_label>
    <arm_group_label>Group B: BCRP probe substrate (rosuvastatin) + regorafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria:

          -  The following criteria apply to ALL patients starting the study treatment:

               -  Patients with histologically confirmed, locally advanced or metastatic solid
                  tumors refractory to standard therapy or in whom regorafenib is considered a
                  standard treatment.

               -  Male or Female Caucasian patients &gt;/= 18 years of age

               -  Women of childbearing potential and men must agree to use adequate contraception
                  before entering the program until at least 8 weeks after the last study drug
                  administration.

               -  Life expectancy of at leat 12 weeks

               -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

               -  Adequate bone marrow and liver function

               -  Estimated creatinine clearance (CLcr) ≥ 30 mL/min as calculated using the
                  Cockroft-Gault (C-G) equation.

               -  Thyroid Stimulating Hormone(TSH) within normal ranges.

          -  The following inclusion criteria apply to Group A (digoxin + regorafenib) patients
             ONLY:

               -  Potassium, magnesium and calcium blood levels within normal range according to
                  the local laboratory.

          -  The following inclusion criteria apply to Group B (rosuvastatin + regorafenib)
             patients ONLY:

               -  Signed genetic informed consent. Patients must be able to understand and willing
                  to sign the written informed consent intended to screen for BCRP and OATP1B1
                  polymorphisms.

          -  Exclusion Criteria:

          -  For ALL patients

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             before start of study medication.

          -  Non-healing wound, skin ulcer, or bone fracture.

          -  Ongoing or active infection.

          -  Other anticancer treatment.

          -  Patients unable to swallow oral medications

          -  For Group A (digoxin + regorafenib):

               -  Family history of sudden cardiac death.

          -  For Group B (rosuvastatin + regorafenib):

               -  Patients with porphyria.

               -  Patients with intestinal or urinary obstructions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herne</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2014</study_first_submitted>
  <study_first_submitted_qc>April 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2014</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Regorafenib</keyword>
  <keyword>Probe substrates</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Cancer</keyword>
  <keyword>Safety</keyword>
  <keyword>Advanced solid malignant tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Digoxin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

